v3.25.1
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Treasury Stock, Common
Balance at beginning of period at Oct. 31, 2023 $ 545,554 $ 372 $ 251,576 $ 409,318 $ (38,141) $ (77,571)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss 6,249     6,249    
Foreign currency translation adjustment 6,081       6,081  
Common dividends ($0.08 per share) (2,645)     (2,645)    
Stock-based compensation activity:            
Expense related to stock-based compensation 583   583      
Stock options exercised 400   22     378
Restricted stock awards granted     (1,357)     1,357
Performance restricted stock units vested     (917)     917
Other (1,193) (1) (1,192)      
Balance at end of period at Jan. 31, 2024 555,029 371 248,715 412,922 (32,060) (74,919)
Balance at beginning of period at Oct. 31, 2023 545,554 372 251,576 409,318 (38,141) (77,571)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss 21,626          
Balance at end of period at Apr. 30, 2024 566,122 371 249,502 425,650 (34,631) (74,770)
Balance at beginning of period at Jan. 31, 2024 555,029 371 248,715 412,922 (32,060) (74,919)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss 15,377     15,377    
Foreign currency translation adjustment (2,571)       (2,571)  
Common dividends ($0.08 per share) (2,649)     (2,649)    
Stock-based compensation activity:            
Expense related to stock-based compensation 782   782      
Stock options exercised 154   5     149
Balance at end of period at Apr. 30, 2024 566,122 371 249,502 425,650 (34,631) (74,770)
Balance at beginning of period at Oct. 31, 2024 1,010,746 513 701,008 430,405 (46,428) (74,752)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (14,885)     (14,885)    
Foreign currency translation adjustment (15,951)       (15,951)  
Common dividends ($0.08 per share) (3,812)     (3,812)    
Purchase of treasury stock (3,698)         (3,698)
Stock-based compensation activity:            
Expense related to stock-based compensation 902   902      
Stock options exercised 214   41     173
Restricted stock awards granted     (1,894)     1,894
Performance restricted stock units vested     (1,300)     1,300
Other (1,400) (1) (1,399)      
Balance at end of period at Jan. 31, 2025 972,116 512 697,358 411,708 (62,379) (75,083)
Balance at beginning of period at Oct. 31, 2024 1,010,746 513 701,008 430,405 (46,428) (74,752)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss 5,630          
Balance at end of period at Apr. 30, 2025 1,001,663 512 698,238 428,483 (27,034) (98,536)
Balance at beginning of period at Jan. 31, 2025 972,116 512 697,358 411,708 (62,379) (75,083)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss 20,515     20,515    
Foreign currency translation adjustment 35,345       35,345  
Common dividends ($0.08 per share) (3,740)     (3,740)    
Purchase of treasury stock (23,496)         (23,496)
Stock-based compensation activity:            
Expense related to stock-based compensation 923   923      
Restricted stock awards granted 0   (43)     43
Balance at end of period at Apr. 30, 2025 $ 1,001,663 $ 512 $ 698,238 $ 428,483 $ (27,034) $ (98,536)